TITLE

FDA eases medication guide distribution requirements

AUTHOR(S)
Traynor, Kate
PUB. DATE
April 2011
SOURCE
American Journal of Health-System Pharmacy;4/15/2011, Vol. 68 Issue 8, p649
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the draft guidance document from the U.S. Food and Drug Administration (FDA) relaxing the agency's stance on the need to distribute medication guides to inpatients which used to be a part of the product's risk evaluation and mitigation strategy (REMS). An overview of possible implications of FDA's enforcement discretion on the provider and the manufacturer is offered. The article suggests that while the providers are happy, it is a setback for the manufacturers of products that have medication guides.
ACCESSION #
59982640

 

Related Articles

  • Don't get burned by OTC topical analgesics. Derbis, Janelle // Pharmacy Today;Nov2012, Vol. 18 Issue 11, p59 

    The article reports that the U.S. Food and Drug Administration (FDA) has identified cases of skin injuries with the use of over the counter (OTC) topical muscle and joint pain relievers containing menthol, methyl salicylate, or capsaicin. It notes that the cases of skin injuries ranged from...

  • Acetaminophen Update. McMann, Mary Carole // Nurse Practitioner World News;Jan/Feb2012, Vol. 17 Issue 1/2, p13 

    The article reports on the measure taken by the U.S. Food and Drug Administration (FDA) to increase the safety of using acetaminophen. It states that the FDA required a warning for prescription medications involving acetaminophen to provide information about the risk of liver damage due to...

  • FDA's safety reform is greeted with scepticism. Moynihan, Ray // BMJ: British Medical Journal (International Edition);2/26/2005, Vol. 330 Issue 7489, p435 

    Reports that a new safety body at the United States Food and Drug Administration is being met with some scepticism by critics. The new drug safety oversight board whose job it will be the oversee the management of drug safety issues and to provide information to doctors and patients more...

  • Educating patients about FDA's MedWatch. Tanzi, Maria G. // Pharmacy Today;Mar2013, Vol. 19 Issue 3, p26 

    The article focuses on patients education on MeWatch Adverse Reporting Program of the U.S. Food and Drug Administration (FDA). It says that the program determines medical products safety hazard signals, and MedWatch reports regarding adverse events linked with use of FDA-regulated drugs can be...

  • Advisory panel votes against Qnexa.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article discusses the disapproval of the weight-loss drug Qnexa by the U.S. Food and Drug Administration (FDA) due to its side effects such as depression, sleep disorders, and other cognitive disorders.

  • Antidote. Siegel, Marc // Medical Marketing & Media;Jul2011, Vol. 46 Issue 7, p12 

    The article focuses on the disadvantage in media-generated hype mentioning the move of the U.S. Food and Drug Administration in announcing the side effects associated in taking the 80 milligram (mg) simvastatin which may cause panic and fear towards using the drug.

  • First reports of serious adverse drug reactions in recent weeks.  // Drugs & Therapy Perspectives;Dec2010, Vol. 26 Issue 12, p22 

    A chart is presented which lists serious adverse drug reactions which were reported in 2010, including reactions which were reported for the drugs amrubicin, cabergoline and clarithromycin.

  • MuckReads Podcast: When Diet Drugs Harm Instead of Help. Bronzan, Nicole Collins // Pro Publica;Apr2015, p1 

    The article introduces a podcast on an investigative report which found that in the last three years, the U.S. Food and Drug Administration (FDA) has approved five new drugs on the market that are potentially harmful.

  • FDA warns of potential intestinal issues with olmesartan medoxomil.  // Cardiology Today;Aug2013, Vol. 16 Issue 8, p18 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the labeling changes to drugs containing olmesartan medoxomil, issuing a warning on its potential for intestinal problems.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics